TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (Pink Sheets: BVTI) today announced that it is under contract with the U.S. Department of Defense (“DoD”) to supply AutovaxID™ bioreactors for the development and application of this platform technology for cell-culture-based vaccine production. This initial contract, valued at approximately $1.5 million, is part of a DoD initiative tasked with developing new bio-manufacturing solutions for the cost effective and rapid production of preventative and therapeutic vaccines for the treatment of infectious diseases and cancers.
